Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr. Schneider C, et al. Among authors: schliemann c. Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. Nat Med. 2017. PMID: 28586337 No abstract available.
Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.
Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, Wiebe K, Müller KM, Hoffmann TK, Groll AH, Werner C, Kessler C, Wiewrodt R, Rudack C, Berdel WE. Mohr M, et al. Among authors: schliemann c. Oncol Lett. 2014 Nov;8(5):1912-1918. doi: 10.3892/ol.2014.2486. Epub 2014 Aug 28. Oncol Lett. 2014. PMID: 25289079 Free PMC article.
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W. Fiedler W, et al. Among authors: schliemann c. Haematologica. 2022 Dec 1;107(12):2977-2982. doi: 10.3324/haematol.2022.281128. Haematologica. 2022. PMID: 36005556 Free PMC article. Clinical Trial. No abstract available.
Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T, Schwöppe C, Liersch R, Schliemann C, Hintelmann H, Bieker R, Berdel WE, Mesters RM. Kessler T, et al. Among authors: schliemann c. Curr Drug Discov Technol. 2008 Mar;5(1):1-8. doi: 10.2174/157016308783769487. Curr Drug Discov Technol. 2008. PMID: 18537561
157 results